Evidence map›Paper›PMID 38888967›Full record

ArticleClinical and translational medicine2024

KMT2A and chronic inflammation as potential drivers of sporadic parathyroid adenoma.

Qin Xu, Ting La, Kaihong Ye, Li Wang, Shasha Wang, Yifeng Hu, Liu Teng, Lei Yan, Jinming Li, Zhenhua Zhang and 10 more

Abstract read
In one paragraph

Article in Clinical and translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Qin XuDepartment of Nephrology, Henan Key Laboratory of Kidney Disease and Immunology of Zhengzhou University People's Hospital, Zhengzhou University People's Hospital ,Henan Provincial People's Hospital, Zhengzhou, China.
Ting LaNational-Local Joint Engineering Research Center of Biodiagnosis & Biotherapy, The Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Kaihong YeTranslational Research Institute, Henan Provincial and Zhengzhou City Key Laboratory of Non-Coding RNA and Cancer Metabolism, Henan International Join Laboratory of Non-Coding RNA and Metabolism in Cancer, Zhengzhou University People's Hospital and Henan Provincial People's Hospital, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China.
Li WangSchool of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.
Shasha WangDepartment of Nephrology, Xinxiang Medical University, Xinxiang, China.
Yifeng HuDepartment of Nephrology, Henan Key Laboratory of Kidney Disease and Immunology of Zhengzhou University People's Hospital, Zhengzhou University People's Hospital ,Henan Provincial People's Hospital, Zhengzhou, China.
Liu TengDepartment of Nephrology, Henan Key Laboratory of Kidney Disease and Immunology of Zhengzhou University People's Hospital, Zhengzhou University People's Hospital ,Henan Provincial People's Hospital, Zhengzhou, China.
Lei YanDepartment of Nephrology, Henan Key Laboratory of Kidney Disease and Immunology of Zhengzhou University People's Hospital, Zhengzhou University People's Hospital ,Henan Provincial People's Hospital, Zhengzhou, China.
Jinming LiTranslational Research Institute, Henan Provincial and Zhengzhou City Key Laboratory of Non-Coding RNA and Cancer Metabolism, Henan International Join Laboratory of Non-Coding RNA and Metabolism in Cancer, Zhengzhou University People's Hospital and Henan Provincial People's Hospital, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China.
Zhenhua ZhangDepartment of Thyroid Surgery, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, China.
Zehua ShaoChildren's Heart Center, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, China.
Yuan Yuan ZhangSchool of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, New South Wales, Australia.
Xiao Hong ZhaoSchool of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, New South Wales, Australia.
Yu Chen FengSchool of Medicine and Public Health, The University of Newcastle, Callaghan, New South Wales, Australia.
Lei JinTranslational Research Institute, Henan Provincial and Zhengzhou City Key Laboratory of Non-Coding RNA and Cancer Metabolism, Henan International Join Laboratory of Non-Coding RNA and Metabolism in Cancer, Zhengzhou University People's Hospital and Henan Provincial People's Hospital, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China.
Mark BakerSchool of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, New South Wales, Australia.
Rick F ThorneTranslational Research Institute, Henan Provincial and Zhengzhou City Key Laboratory of Non-Coding RNA and Cancer Metabolism, Henan International Join Laboratory of Non-Coding RNA and Metabolism in Cancer, Zhengzhou University People's Hospital and Henan Provincial People's Hospital, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China.
Xu Dong ZhangTranslational Research Institute, Henan Provincial and Zhengzhou City Key Laboratory of Non-Coding RNA and Cancer Metabolism, Henan International Join Laboratory of Non-Coding RNA and Metabolism in Cancer, Zhengzhou University People's Hospital and Henan Provincial People's Hospital, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China.
Feng-Min ShaoDepartment of Nephrology, Henan Key Laboratory of Kidney Disease and Immunology of Zhengzhou University People's Hospital, Zhengzhou University People's Hospital ,Henan Provincial People's Hospital, Zhengzhou, China.
Huixia CaoDepartment of Nephrology, Henan Key Laboratory of Kidney Disease and Immunology of Zhengzhou University People's Hospital, Zhengzhou University People's Hospital ,Henan Provincial People's Hospital, Zhengzhou, China.ORCID 0000-0002-4729-2210

Funding

Cancer Council NSW Project Grant, Australia RG21-10Medical Science and Technology Project of Henan Province, China HGJ20190615Medical Science and Technology Project of Henan Province, China SBGJ2018062National Health and Medical Research Council APP2016686National Key Research and Development Program of China 2018YFC1311202National Natural Science Foundation of China 82002571National Natural Science Foundation of China 82372638Talent Project of Henan Provincial People's Hospital, Major Public Welfare Projects in Henan Province 201300310700
6 · The paper itself

Abstract

backgroundSporadic parathyroid adenoma (PA) is the most common cause of hyperparathyroidism, yet the mechanisms involved in its pathogenesis remain incompletely understood.

methodsSurgically removed PA samples, along with normal parathyroid gland (PG) tissues that were incidentally dissected during total thyroidectomy, were analysed using single-cell RNA-sequencing with the 10× Genomics Chromium Droplet platform and Cell Ranger software. Gene set variation analysis was conducted to characterise hallmark pathway gene signatures, and single-cell regulatory network inference and clustering were utilised to analyse transcription factor regulons. Immunohistochemistry and immunofluorescence were performed to validate cellular components of PA tissues. siRNA knockdown and gene overexpression, alongside quantitative polymerase chain reaction, Western blotting and cell proliferation assays, were conducted for functional investigations.

resultsThere was a pervasive increase in gene transcription in PA cells (PACs) compared with PG cells. This is associated with high expression of histone-lysine N-methyltransferase 2A (KMT2A). High KMT2A levels potentially contribute to promoting PAC proliferation through upregulation of the proto-oncogene CCND2, which is mediated by the transcription factors signal transducer and activator of transcription 3 (STAT3) and GATA binding protein 3 (GATA3). PA tissues are heavily infiltrated with myeloid cells, while fibroblasts, endothelial cells and macrophages in PA tissues are commonly enriched with proinflammatory gene signatures relative to their counterparts in PG tissues.

conclusionsWe revealed the previously underappreciated involvement of the KMT2A‒STAT3/GATA3‒CCND2 axis and chronic inflammation in the pathogenesis of PA. These findings underscore the therapeutic promise of KMT2A inhibition and anti-inflammatory strategies, highlighting the need for future investigations to translate these molecular insights into practical applications. HIGHLIGHTS: Single-cell RNA-sequencing reveals a transcriptome catalogue comparing sporadic parathyroid adenomas (PAs) with normal parathyroid glands. PA cells show a pervasive increase in gene expression linked to KMT2A upregulation. KMT2A-mediated STAT3 and GATA3 upregulation is key to promoting PA cell proliferation via cyclin D2. PAs exhibit a proinflammatory microenvironment, suggesting a potential role of chronic inflammation in PA pathogenesis.

Indexed as

AdenomaHistone-Lysine N-MethyltransferaseInflammationParathyroid NeoplasmsCell ProliferationHumansMyeloid-Lymphoid Leukemia ProteinHistone-Lysine N-MethyltransferaseMyeloid-Lymphoid Leukemia ProteinCCND2cyclin D2epigeneticsKMT2Asingle‐cell analysissporadic parathyroid adenoma

Identifiers

PMID38888967
PMCPMC11185127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.